Treatment of neoplasms with viruses

• US 8,105,578 B2
• Filed: 01/29/2007
• Issued: 01/31/2012
• Est. Priority Date: 10/09/1997
• Status: Expired due to Fees

• Current Assignee: Wellstat Biologics Corp.
• Original Assignee: Wellstat Biologics Corp.
• Inventors: Roberts, Michael S., Lorence, Robert M., Groene, William S., Rabin, Harvey, von Borstel, Reid W.
• Primary Examiner(s): Lucas, Zachariah
• Assistant Examiner(s): KINSEY WHITE, NICOLE ERIN
• Application Number:
  US11/698,947
• Publication Number:
  US 20080057037A1
• Time in Patent Office: 1,828 Days
• Field of Search: 435/320.1
• US Class Current: 424/93.6
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/768 Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
• CPC Class Codes: A61K 38/21 Interferons [IFN]
• CPC Class Codes: A61K 39/42 viral
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 2760/18132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
• CPC Class Codes: C12N 2770/36132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.

Claims

1. A method of infecting a cell of a neoplasm in a mammal with a virus, the method comprising administering an interferon-sensitive, replication-competent vaccinia virus to the mammal,

wherein the virus comprises one or more mutations in one or more genes selected from the group consisting of K3L, E3L, and B18R,

wherein the one or more mutations increases the interferon sensitivity of the virus.

2. The method of claim 1, wherein the virus comprises one or more mutations in two or more genes selected from the group consisting of K3L, E3L, and B18R.

3. The method of claim 1, wherein the vaccinia virus replicates at least 100-fold less in the presence of interferon compared to in the absence of interferon.

4. The method of claim 1, wherein the vaccinia virus replicates at least 1000-fold less in the presence of interferon compared to in the absence of interferon.

5. The method of claim 1, wherein said administering is systemic.

6. The method of claim 1, wherein said administering is intravenous.

7. The method of claim 1, wherein said administering is intratumoral.

8. The method of claim 1, wherein the virus is administered as more than one dose.

9. The method of claim 8, wherein the first dose is a desensitizing dose.

10. The method of claim 8, wherein the first dose is administered intravenously.

11. The method of claim 8, wherein a dose is administered intraperitoneally subsequent to the first dose.

12. The method of claim 8, wherein a dose is administered intravenously subsequent to the first dose.

13. The method of claim 1, wherein a dose is administered intra-arterially subsequent to the first dose.

14. The method of claim 1, resulting in reducing pain in the mammal.

15. The method of claim 1, resulting in regression of the neoplasm.

16. The method of claim 8, wherein multiple courses of virus are administered.

17. The method of claim 1, wherein the virus is a clonal virus.

18. The method as in claim 17, wherein the clonal virus is obtained by plaque purification or obtained by limiting dilutions.

19. The method of claim 1, wherein the neoplasm is a cancer.

20. The method of claim 19, wherein the cancer is selected from the group consisting of lung, colon, prostate, breast, ascites and brain cancer.

21. The method of claim 1, wherein the neoplasm is a solid tumor.

22. The method of claim 1, wherein the neoplasm is a glioblastoma.

23. The method of claim 1, wherein the virus contains a heterologous gene encoding a pro-drug activating enzyme.

24. The method of claim 1, wherein the virus contains a heterologous gene encoding an interferon to permit the viral expression of the heterologous gene.

25. The method of claim 1, wherein at least one dose of the virus is administered over the course of at least 4 minutes.

26. The method of claim 1, further comprising administering IFN, before, during or after administration of the virus.

27. The method of claim 26, wherein the interferon is selected from the group consisting of an α

-IFN, a β

-IFN, a ω

-IFN, a γ

-IFN, and a synthetic consensus form of IFN.

28. The method of claim 1, further comprising administering before, during or after administration of the virus a compound selected from the group consisting of a purine nucleoside analog, a tyrosine kinase inhibitor, a cimetidine, a mitochondrial inhibitor, a chemotherapeutic agent, a cytokine, an immunosuppressant and a second virus.

29. The method of claim 28, wherein the cytokine is a GM-CSF, a TNF or an IL-2.

30. The method of claim 28, wherein the immunosuppressant is a corticosteroid.

31. The method of claim 1, wherein the mammal is a human.

32. The method of claim 1, wherein the neoplasm is from 2 centimeters (cm) to 5 cm.

33. The method of claim 1, wherein the neoplasm is at least 5 cm.

34. The method of claim 1, wherein the neoplasm is at least 2 cm.

35. The method of claim 1, wherein the neoplasm is at least 1 cm.

36. The method of claim 1, wherein the neoplasm is at least 300 mm³ in volume.

37. The method of claim 1, wherein the neoplasm is from about 1% to about 2% of the total body weight of the mammal.

38. The method of claim 1, wherein the neoplasm does not respond to a chemotherapy.

39. The method of claim 1, comprising a step of screening a cell of the neoplasm for a protein, or mRNA encoding a protein, selected from the group consisting of p68 protein kinase, C-Myc, C-Myb, ISGF-3, IRF-I, IFN receptor, and p58.

40. The method of claim 1, comprising subjecting a sample from the mammal to an immunoassay to detect the amount of receptor for the virus that is present, and if the receptor is present, administering the virus to the mammal.

41. The method of claim 1, wherein the virus further comprises one or more attenuating mutations in at least two genes selected from the group consisting of vaccinia growth factor, thymidine kinase, thymidylate kinase, DNA ligase, ribonucleotide reductase and dUTPase.

42. The method of claim 1, wherein the virus further comprises one or more attenuating mutations in the vaccinia growth factor and the thymidine kinase gene.

43. The method of claim 1, wherein the virus comprises one or more mutations in the K3L gene.

44. The method of claim 43, wherein the virus further comprises one or more attenuating mutations in a thymidine kinase gene.

45. The method of claim 43, wherein the virus further comprises one or more attenuating mutations in a vaccinia growth factor gene.

46. The method of claim 43, wherein the virus further comprises one or more attenuating mutations in a thymidylate kinase gene.

47. The method of claim 43, wherein the virus further comprises one or more attenuating mutations in a DNA ligase gene.

48. The method of claim 43, wherein the virus further comprises one or more attenuating mutations in a ribonucleotide reductase gene.

49. The method of claim 43, wherein the virus further comprises one or more attenuating mutations in a dUTPase gene.

50. The method of claim 1, wherein the virus comprises one or more mutations in the E3L gene.

51. The method of claim 50, wherein the virus further comprises one or more attenuating mutations in a thymidine kinase gene.

52. The method of claim 50, wherein the virus further comprises one or more attenuating mutations in a vaccinia growth factor gene.

53. The method of claim 50, wherein the virus further comprises one or more attenuating mutations in a thymidylate kinase gene.

54. The method of claim 50, wherein the virus further comprises one or more attenuating mutations in a DNA ligase gene.

55. The method of claim 50, wherein the virus further comprises one or more attenuating mutations in a ribonucleotide reductase gene.

56. The method of claim 50, wherein the virus further comprises one or more attenuating mutations in a dUTPase gene.

57. The method of claim 1, wherein the virus comprises one or more mutations in the B18R gene.

58. The method of claim 57, wherein the virus further comprises one or more attenuating mutations in a thymidine kinase gene.

59. The method of claim 57, wherein the virus further comprises one or more attenuating mutations in a vaccinia growth factor gene.

60. The method of claim 57, wherein the virus further comprises one or more attenuating mutations in a thymidylate kinase gene.

61. The method of claim 57, wherein the virus further comprises one or more attenuating mutations in a DNA ligase gene.

62. The method of claim 57, wherein the virus further comprises one or more attenuating mutations in a ribonucleotide reductase gene.

63. The method of claim 57, wherein the virus further comprises one or more attenuating mutations in a dUTPase gene.